Blueprint Medicines (BPMC) Tops Q3 EPS by 17c

Blueprint Medicines (NASDAQ: BPMC) reported Q3 EPS of ($0.62), $0.17 better than the analyst estimate of ($0.79). Revenue for the quarter came in at $6.16 million versus the consensus estimate of $6.06 million.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.

You May Also Be Interested In

• Wolfe Research starts Ferrari at Outperform, sees 'solid upside potential'
• Kura Sushi (KRUS) Tops Q3 EPS by 3c; offers outlook
• TRNR agrees to acquire STEPR, raises 2026 revenue guidance to $50M